1α,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of synthetic vitamin D3 analog, 1α,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 5-6, 1996, Pages 405-412

  Siu Caldera, Mei Ling ^a   Clark, Jeffrey W ^a   Santos Moore, Anabela ^a   Peleg, Sara ^b   Liu, Yan Yun ^b   Uskokovíc, Milan R ^c   Sharma, Surendra ^a   Reddy, G Satyanarayana ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL DERIVATIVE; DRUG METABOLITE; GROWTH HORMONE RECEPTOR; OSTEOCALCIN; 1,25 DIHYDROXY 16 ENE VITAMIN D3; 1,25 DIHYDROXY 24 OXO 16 ENE VITAMIN D3; 1,25-DIHYDROXY-16-ENE-VITAMIN D3; 1,25-DIHYDROXY-24-OXO-16-ENE-VITAMIN D3; CALCITRIOL RECEPTOR; DRUG DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG METABOLISM; GENE ACTIVATION; GENE CONSTRUCT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MASS SPECTROMETRY; NONHUMAN; OSTEOSARCOMA CELL; RAT; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY;

CALCITRIOL; CELL DIFFERENTIATION; CELL DIVISION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LEUKEMIA, MYELOID; RECEPTORS, CALCITRIOL; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030332981     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00134-3     Document Type: Article

References (24)

1. 1. Bouillon R., Okamura W. H. and Norman A. W.: Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 16 (1995) 200-257.
2. 3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leuk. Res. 18 (1994) 453-463.
3. 3. Bikle D. D., Gee E. and Pillai S.: Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. J. Invest. Dermatol. 101 (1993) 713-718.
4. 4. Zhou J.-Y., Norman A. W., Lubbert M., Collins E. D., Uskokovic M. R. and Koeffler H. P.: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74 (1989) 82-93.
5. 3 in rat kidney by on-line high performance liquid chromatography electrospray tandem mass spectrometry. Biochem. Pharmacol. 49 (1994) 1099-1110.
6. 3 in kidney: influence of structural modification of D-ring on side chain metabolism. Bioorg. Med. Chem. Lett. 3 (1993) 1879-1884.
7. 3 produced in rat kidney. Biochemistry 26 (1987) 324-331.
8. 3 through C-24 oxidation pathway. Biochemistry 28 (1989) 1763-1769.
9. 9. Ozono K., Liao S. A., Kerner S, A., Scott R. A. and Pike J. W.: The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J. Biol. Chem. 265 (1990) 21881-21888.
10. 10. Lopata M. A., Cleveland D. W. and Sollner-Webb B.: High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment. Nucl. Acids Res. 12 (1984) 5707-5717.
11. 3 into their respective lactones. Endocrinology 136 (1995) 4195-4203.
12. 3 is a mixture of both C-24R and C-24S epimers. Arch. Biochem. Biophys. 234 (1984) 97-104.
13. 3 between chickens and rats. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7485-7489.
14. 3 and its analogs. J. Bone Min. Res. 9 (1994) 1277-1288.
15. 3 is due to reduced catabolism and altered protein binding. Biochem. Pharmacol. 47 (1994) 987-993.
16. 3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem. 270 (1995) 10551-10558.
17. 3 by normal human peripheral monocytes. Endocrinology 133 (1993) 2719-2723.
18. 3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J. Steroid Biochem. Molec. Biol. 41 (1992) 231-240.
19. 3. J. Biol. Chem. 268 (1993) 2022-2030.
20. 3. J. Biol. Chem. 269 (1994) 2971-2981.
21. 3. J. Biol. Chem. 254 (1979) 7163-7167.
22. 3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 135 (1994) 2818-2821.
23. 3 derivatives in inducing differentiation of HL-60 human promyelocytic leukemia cells. J. Pharm. Dyn. 7 (1984) 962-968.
24. 3. Arch. Biochem. Biophys. 224 (1983) 671-676.